All the news Showing 10 of 53 articles from: Treatment for previous non-responders & relapsersGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Re-treatment of hepatitis C is highly effective after the first combination fails Keith Alcorn / 24 June 2022 Two combinations proved highly effective in curing hepatitis C in people who had experienced the failure of a previous combination containing an NS5A inhibitor, studies in Europe and New Zealand show. The findings, ... Three-drug regimen plus ribavirin cures the hardest-to-treat hepatitis C patients Keith Alcorn / 08 December 2021 People who have experienced failure of multiple courses of direct-acting antiviral treatment can be cured of hepatitis C with a combination of three direct-acting antivirals plus ribavirin, a review of heavily treatment-experienced patients ... ‘Real-world’ studies in Germany and the USA confirm high rates of sustained virological response with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in individuals with chronic HCV infection failing DAAs EASL / 12 April 2019 Antiviral resistance testing in the management of hepatitis C Public Health England / 17 December 2018 US regulator approves Gilead's Vosevi combo pill for hepatitis C retreatment Liz Highleyman / 19 July 2017 On 18 July the US Food and Drug Administration (FDA) approved Gilead Sciences' Vosevi, a new once-daily combination pill containing sofosbuvir, velpatasvir, and voxilaprevir. Vosevi was approved as "salvage therapy" ... Early Access to Medicines Scheme (EAMS) Granted to AbbVie’s Investigational Pan-genotypic Regimen for Chronic Hepatitis C in UK AbbVie press release / 10 May 2017 Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C Merck press release / 24 April 2017 EASL issues new hepatitis C treatment recommendations for all genotypes Liz Highleyman / 26 September 2016 The European Association for the Study of the Liver (EASL) released its latest recommendations on treatment of hepatitis C at a special meeting last Thursday in Paris. The updated guidelines now include highly ... Next-generation HCV treatments should benefit challenging patient groups Digestive Disease Week blog / 23 May 2016 High HCV cure rate demonstrated for people retreated after failure of short course direct-acting antiviral therapy Liz Highleyman / 09 December 2015 People with hepatitis C who did not achieve sustained virological response with a prior short course of direct-acting antiviral (DAA) therapy had a high likelihood of being cured if treated again with sofosbuvir/ledipasvir ... ← First12345...6Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive